Patient characteristics
| No. of patients | 44 |
| Treatment cycles | 131 |
| PSa (ECOG 0/1) | 26/18 |
| Gender (M/F) | 25/19 |
| Median age (range) | 45 (19–71) |
| Sites of metastasis | |
| Lymph node/s.c. | 8 (18%) |
| Visceral | 36 (82%) |
| No. of metastatic sites | |
| 1 | 10 (25%) |
| 2 | 14 (35%) |
| >2 | 16 (40%) |
| Prior therapy | 33 (75%) |
| XRT | 8 (18%) |
| Systemic therapy | 29 (66%) |
| IFN | 23 (53%) |
| Other biological medication | 8 (18%) |
| Chemo or IL-2 | 0 |
| Ocular primary | 2 (5%) |
a PS, performance status; XRT, radiation therapy.